Alpha Teknova (TKNO) Non-Current Deferred Tax Liability (2020 - 2026)
Alpha Teknova's (TKNO) quarterly Non-Current Deferred Tax Liability came in at $925000.0 in Q1 2026, up 9.08% year-on-year from $848000.0 in Q1 2025, and up 5.23% on a QoQ basis from $879000.0 in Q4 2025.
Alpha Teknova (TKNO) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Alpha Teknova (TKNO) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $925000.0 in Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability rose 9.08% year-over-year to $925000.0 in Q1 2026; TTM through Mar 2026 was $925000.0, a 9.08% increase from a year earlier, with the FY2025 full-year figure at $879000.0, up 6.29% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $925000.0, up from $879000.0 in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for TKNO reached as high as $2.8 million in Q1 2022 and fell as low as $827000.0 in Q4 2024.
- Historically, Non-Current Deferred Tax Liability has averaged $1.2 million across 5 years, with a median of $925000.0 in 2026.
- Across the five-year window, Non-Current Deferred Tax Liability slumped 61.21% in 2022 and rose 9.11% in 2025, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $1.2 million in 2022, then dropped by 24.86% to $919000.0 in 2023, then decreased by 10.01% to $827000.0 in 2024, then advanced by 6.29% to $879000.0 in 2025, then increased by 5.23% to $925000.0 in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $925000.0 in Q1 2026, $879000.0 in Q4 2025, and $946000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alpha Teknova | 278.75 Mn | 260.97 Mn | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 925,000.00 |
| Mar 31, 2026 | 925,000.00 |
| Dec 31, 2025 | 879,000.00 |
| Dec 31, 2025 | 879,000.00 |
| Sep 30, 2025 | 946,000.00 |
| Sep 30, 2025 | 946,000.00 |
| Jun 30, 2025 | 868,000.00 |
| Jun 30, 2025 | 868,000.00 |
| Mar 31, 2025 | 848,000.00 |
| Mar 31, 2025 | 848,000.00 |
| Dec 31, 2024 | 827,000.00 |
| Dec 31, 2024 | 827,000.00 |
| Sep 30, 2024 | 867,000.00 |
| Sep 30, 2024 | 867,000.00 |
| Jun 30, 2024 | 875,000.00 |
| Jun 30, 2024 | 875,000.00 |
| Mar 31, 2024 | 884,000.00 |
| Mar 31, 2024 | 884,000.00 |
| Dec 31, 2023 | 919,000.00 |
| Dec 31, 2023 | 919,000.00 |